Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- MDNA.TO
- Price
- 0.82
- Stock movement down
- -0.01 (-1.20%)
- Company name
- Medicenna Therapeutics Corp
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 68.40M
- Ent value
- 60.45M
- Price/Sales
- -
- Price/Book
- 6.68
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -3.13%
- 1 year return (CAGR)
- -37.88%
- 3 year return (CAGR)
- -5.45%
- 5 year return (CAGR)
- -30.94%
- 10 year return (CAGR)
- -
Last updated: 2026-02-24
DIVIDENDS
MDNA.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 6.68 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 83.41M |
| EPS (TTM) | -0.17 |
| FCF per share (TTM) | -0.48 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -59.00K |
| Operating income (TTM) | -21.82M |
| Net income (TTM) | -13.81M |
| EPS (TTM) | -0.17 |
| EPS (1y forward) | -0.37 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 15.75M |
| Net receivables | 1.26M |
| Total current assets | 17.87M |
| Goodwill | 0.00 |
| Intangible assets | 49.00K |
| Property, plant and equipment | 120.00K |
| Total assets | 18.04M |
| Accounts payable | 3.65M |
| Short/Current long term debt | 149.00K |
| Total current liabilities | 4.46M |
| Total liabilities | 7.80M |
| Shareholder's equity | 10.24M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -20.58M |
| Capital expenditures (TTM) | 66.00K |
| Free cash flow (TTM) | -40.08M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -134.89% |
| Return on Assets | -76.58% |
| Return on Invested Capital | -134.89% |
| Cash Return on Invested Capital | -391.36% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.84 |
| Daily high | 0.85 |
| Daily low | 0.80 |
| Daily Volume | 38K |
| All-time high | 7.00 |
| 1y analyst estimate | 3.88 |
| Beta | 1.87 |
| EPS (TTM) | -0.17 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| MDNA.TO | S&P500 | |
| Current price drop from All-time high | -88.29% | -1.82% |
| Highest price drop | -96.86% | -56.47% |
| Date of highest drop | 1 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -60.79% | -10.84% |
| Avg time to new high | 72 days | 12 days |
| Max time to new high | 1435 days | 1805 days |
COMPANY DETAILS
Marketcap
68.40M
Marketcap category
Small-cap
Description
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Employees
18
Website
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
TORONTO and HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the deve...
February 18, 2026
The Canadian market has recently experienced some positive shifts, with the unemployment rate showing signs of stabilization and inflation gradually easing. In such a landscape, investors often look f...
February 16, 2026
Medicenna to present updated internal and external data sets related to bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit to be held in Boston from 17-19 February 2026 Updated ABIL...
February 13, 2026
TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the deve...
February 13, 2026
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
January 26, 2026
Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential fo...
January 15, 2026
On December 15, 2025, Fahar Merchant, President and Chief Executive Officer of Medicenna Therapeutics Corp. ("Medicenna"), purchased an aggregate of 32,000 common shares of Medicenna (the "Shares") th...
December 15, 2025
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case ...
December 10, 2025
TORONTO and HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the deve...
December 9, 2025
Updated MDNA11 Clinical Data from the ABILITY-1 Study will be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on 10th December, 2025 Fondazion Melanoma Onus will...
November 13, 2025
Next page